Is Trident Lifeline overvalued or undervalued?

As of 24 September 2025, Trident Lifeline's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 21.02, an EV to EBITDA ratio of 15.95, and a PEG ratio of 0.25, which suggests that while growth prospects may be favorable, the current price does not reflect a compelling investment opportunity.
In comparison to its peers, Trident Lifeline's valuation appears less attractive. For instance, Sun Pharma has a significantly higher PE ratio of 34.03, while Cipla, considered attractive, has a PE ratio of 22.99. Additionally, Trident's ROCE stands at 9.85%, which is lower than the industry average, further supporting the notion of overvaluation. Despite recent stock performance showing a 3.66% return over the past week compared to a -1.18% return for the Sensex, the overall valuation metrics suggest that Trident Lifeline is not a favorable investment at its current price.